Literature DB >> 28342195

A simple self-diagnosis tool to assess the prevalence of dermatoporosis in France.

J-H Saurat1, V Mengeaud2, V Georgescu3, C Coutanceau3, K Ezzedine4, C Taïeb5,6.   

Abstract

IMPORTANCE: The term dermatoporosis has been proposed to describe clinical signs and functional consequences of age-related extreme skin fragility.
OBJECTIVE: To create a simple dermatoporosis self-diagnosis tool (IDA: Index Dermatoporosis Assessment) and to use this tool to estimate the prevalence of dermatoporosis in France. DESIGN, SETTING AND PARTICIPANTS: A specific dermatoporosis questionnaire was developed with the help of senior dermatologists and survey experts. This questionnaire was submitted to consecutive individuals aged ≥65 years who consulted a dermatologist. At the end of the consultation, the dermatologist was asked to assess 'whether or not' dermatoporosis was present. In a second step, the final questionnaire was mailed to a representative sample of the French population aged ≥65 years in order to estimate the prevalence of dermatoporosis.
RESULTS: The initial questionnaire, consisting of two modules (24 questions), was validated in 173 individuals aged ≥65 years) during a dermatologist consultation. Dermatologists diagnosed 46% of the individuals with dermatoporosis. The final validated questionnaire consisted of 14 items, 12 consisting in presence or absence of clinical signs and two items consisting of the self-assessment by individuals of skin ageing on neckline and hands (none/moderate/significant/very significant). A scoring system was generated to quote quantitatively dermatoporosis (from 0 if no sign of dermatoporosis to 20 maximal dermatoporosis). The area under the receiver operator curve was 0.8535, indicating a very good ability of the questionnaire to differentiate between individuals. A cut-off value of 11 was linked to positive and negative predictive values of 0.78 and 0.81, respectively. In a second step, using the questionnaire in a representative sample of the French population (n = 533), the estimated overall prevalence of dermatoporosis was 37.5% in French subjects aged ≥65 years [27.5% (males) vs. 43.9% (females); P < 0.05]. The estimated prevalence of dermatoporosis was twice higher in subjects with eczema or atopic dermatitis during childhood than in the population without dermatoporosis (60.6% vs. 33.4%, P < 0.001). Individuals with dermatoporosis also reported a higher prevalence of itching, long-term corticosteroid use, anticoagulant use and prior sun exposure. CONCLUSIONS AND RELEVANCE: Using a new simple dermatoporosis self-diagnosis tool, this study provides a previously unprecedented insight into the high prevalence of dermatoporosis in elderly individuals. IDA questionnaire is a short (14-item) and easy to use tool for evaluating dermatoporosis in adults and may allow an easy evaluation of each subject.
© 2017 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2017        PMID: 28342195     DOI: 10.1111/jdv.14240

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  4 in total

Review 1.  Chronic Skin Fragility of Aging: Current Concepts in the Pathogenesis, Recognition, and Management of Dermatoporosis.

Authors:  Joseph M Dyer; Richard A Miller
Journal:  J Clin Aesthet Dermatol       Date:  2018-01-01

2.  Morphological Analysis of Dermatoporosis by in vivo Reflectance Confocal Microscopy and Ultrasonography.

Authors:  Sébastien Menzinger; Jean-Hilaire Saurat; Gürkan Kaya
Journal:  Dermatopathology (Basel)       Date:  2020-03-17

Review 3.  Dermatoporosis - The Chronic Cutaneous Fragility Syndrome.

Authors:  Uwe Wollina; Torello Lotti; Aleksandra Vojvotic; Andreas Nowak
Journal:  Open Access Maced J Med Sci       Date:  2019-08-30

4.  Senile Purpura: Clinical Features and Related Factors.

Authors:  Soo Ick Cho; Ji Won Kim; Gyeongyeon Yeo; Dongmuk Choi; Junggyo Seo; Hyun-Sun Yoon; Jin Ho Chung
Journal:  Ann Dermatol       Date:  2019-07-01       Impact factor: 1.444

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.